Sonio, established in 2020, operates at the intersection of AI, Health Care, and Medical Devices. It offers a customizable workflow and practice management solution aimed at enhancing prenatal care. With the backing of AI, Sonio provides an innovative platform to improve ultrasound practices, focusing on automation, quality control, and efficient diagnostics.
The company's flagship product, the AI-enhanced Sonio Detect, is FDA 510(k) cleared, reflecting a significant milestone in quality assurance. The platform emerges from over five years of joint research between fetal medicine experts and artificial intelligence specialists, underlining its robust scientific foundation.
Acquired by Samsung Medison Co., Ltd in May 2024, with a substantial $92.70M investment, Sonio is headquartered in the United States. Its acquisition signifies a strategic alignment with Samsung Medison's commitment to revolutionizing prenatal care through technological advancement.